Nanoparticle mRNA Vaccins against Coronavirus and Emerging Variants (Q3989360): Difference between revisions
Jump to navigation
Jump to search
(Removed claim: country (P32): Kingdom of the Netherlands (Q213)) |
(Changed an Item: Fixing dateand country) |
||||||||||||||
Property / start time | |||||||||||||||
1 April 2021
| |||||||||||||||
Property / start time: 1 April 2021 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / end time | |||||||||||||||
31 March 2023
| |||||||||||||||
Property / end time: 31 March 2023 / rank | |||||||||||||||
Normal rank | |||||||||||||||
Property / country | |||||||||||||||
Property / country: Netherlands / rank | |||||||||||||||
Normal rank |
Revision as of 10:56, 14 December 2021
Project Q3989360 in Netherlands
Language | Label | Description | Also known as |
---|---|---|---|
English | Nanoparticle mRNA Vaccins against Coronavirus and Emerging Variants |
Project Q3989360 in Netherlands |
Statements
293,087.67 Euro
0 references
1,434,730.4 Euro
0 references
20.428 percent
0 references
1 April 2021
0 references
31 March 2023
0 references
20Med Therapeutics
0 references
7522 NB
0 references
Identifiers
OP-2014-2023-Oost-PROJ-01040
0 references